Trial-Results center  
Clinical trial results database in 100 Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - hormonal replacement therapy - all type of patients

cardiovascular prevention - hormonal replacement therapy - secondary prevention


Related trials

WISDOM, 2007 - combined estrogen and progestogen vs placebo

EAGAR, 2006 - combined estrogen and progestogen vs placebo

WHISP, 2006 - combined estrogen and progestogen vs placebo

WELL-HART (estrogen-progestin), 2003 - combined estrogen and progestogen vs placebo

WELL-HART (estrogen alone), 2003 - estrogen vs placebo

WAVE, 2002 - combined estrogen and progestogen vs placebo

WHI, 2002 - combined estrogen and progestogen vs placebo

Schulman (NHLBI) (estrogen alone), 2002 - estrogen vs placebo

ESPRIT, 2002 - estrogen vs placebo

Schulman (NHLBI) (estrogen-progestogen), 2002 - combined estrogen and progestogen vs placebo

WEST, 2001 - estrogen vs placebo

EPAT, 2001 - estrogen vs placebo

ERA (estrogen alone ), 2000 - estrogen vs placebo

EVTET, 2000 - combined estrogen and progestogen vs placebo

ERA (estrogen plus medroxyprogesterone), 2000 - combined estrogen and progestogen vs placebo

Hall, 1998 - combined estrogen and progestogen vs placebo

HERS, 1998 - combined estrogen and progestogen vs placebo

PEPI, 1995 - hormonal replacement therapy vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of hormonal replacement therapy
  • All clinical trials of combined estrogen and progestogen
  •  

    EVTET study, 2000

    download pdf: combined estrogen and progestogen | hormonal replacement therapy for cardiovascular prevention

    Treatments

    Studied treatment 2 mg estradiol plus 1 mg norethisterone acetate, 1 tablet daily
    Control treatment placebo

    Patients

    Patients postmenopausal women younger than 70 years who had suffered previous DVT or PE
    Inclusion criteria Previous VTE verified by venography or ultrasound in cases of DVT, and lung-scan, helical computed tomography, or angiography in cases of PE; no natural menstruation for at least one year
    Exclusion criteria current use or use of anticoagulants within the last three months; familial antithrombin deficiency; any type of malignant diseases including known, suspected or past history of carcinoma of the breast; acute or chronic liver disease or history of liver disease in which liver function tests had failed to return to normal; porphyria, known drug abuse or alcoholism; life expectancy less than two years
    Baseline characteristics
    type of prevention (secondary prevention 
    Age (years) 55.8 y 
    diabetes (%) 2.1% 
    hypertension (%) 17.1% 
    BMI (kg/m²) 27.1 

    Method and design

    Randomized effectives 71 / 69 (studied vs. control)
    Design Parallel groups
    Blinding double-blind
    Follow-up duration 24 months
    Premature discontinuation Premature discontinuation, reason unknown
    Number of centre single center
    Geographic area Norway
    Primary endpoint recurrent deep venous thrombosis or pulmonary embolism


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    puylmonary embolism

    3 / 71
    1 / 69
    classic 2,92 [0,31;27,35]

    Venous thromboembolism

    8 / 71
    1 / 69
    classic 7,77 [1,00;60,53]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    puylmonary embolism 3 / 71 (4,2%) 1 / 69 (1,4%) 2,92 [0,31;27,35]   10510
    Venous thromboembolism 8 / 71 (11,3%) 1 / 69 (1,4%) 7,77 [1,00;60,53]   10510
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 10510: Gabriel SR, Carmona L, Roque M, Sánchez GL, Bonfill XHormone replacement therapy for preventing cardiovascular disease in post-menopausal women.Cochrane Database Syst Rev 2005;:CD002229

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    puylmonary embolism 4,23% 1,45% 2,8%
    Venous thromboembolism 11,27% 1,45% 9,8%

    Meta-analysis of all similar trials:

    hormonal replacement therapy in cardiovascular prevention for all type of patients

    hormonal replacement therapy in cardiovascular prevention for secondary prevention



    Reference(s)

    Trials register # NA
    • Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).. Thromb Haemost 2000;84:961-7
      Pubmed | Hubmed | Fulltext

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100